Hogan Lovells continues growth with pharmaceutical and biotechnology regulatory counsel Scott Kaplan's move to the firm's Boston office

Kaplan arrives from the Hogan Lovells Washington, D.C. office, where he has been a member of the Pharmaceutical and Biotechnology practice. This leveraging of the firm's Global Regulatory platform is the latest example of the firm's expansion of its Boston office. This builds off of the recent additions of Life Sciences Transactions partner Suzanne Filippi, the Intellectual Property team of Kristin Connarn and Bob Underwood, and Antitrust senior counsel David Walsh.

Drawing on his previous experience as Associate Chief Counsel for Enforcement at the Food and Drug Administration (FDA) and his years in the firm's Washington, D.C. office, Kaplan helps pharmaceutical and biotechnology clients achieve and maintain compliance with FDA requirements, focusing on FDA inspections and enforcement actions, current good manufacturing practice (cGMP) requirements, Drug Supply Chain Security Act (DSCSA) implementation, and data integrity responsibilities, among other compliance needs.

"Scott provides creative and practical solutions to help our clients successfully operate in a highly regulated environment, relying on his knowledge of the law, his understanding of the client's business, and his years of experience at FDA. His move to Boston further expands our life sciences regulatory capabilities in this key market," said Philip Katz, Head of the Pharmaceutical and Biotechnology practice at Hogan Lovells.

"We are excited to welcome Scott to the Boston office as part of our continued growth and expansion. We are pleased to be able to offer Scott's exceptional knowledge of FDA compliance matters, combined with the firm's preeminent Regulatory practice, to our life sciences clients in the Boston area and beyond," added Maria Durant, Office Managing Partner of the Hogan Lovells Boston office.

Kaplan earned his J.D., magna cum laude (Order of the Coif) from the University of Pennsylvania Law School, along with a master's degree in bioethics from the university's Center for Bioethics in 2009; his B.A., cum laude, also from the University of Pennsylvania, was awarded in 2002.